https://www.axios.com/2023/03/21/drug-shortages-upend-cancer-treatments
Supplies of some essential drugs used in hospitals are hitting 10-year lows, forcing rationing and pharmacy workarounds.
Driving the news: Drug shortages are the worst they’ve been in a decade, according to the American Society of Health-System Pharmacists — a sign of how much we rely on low-margin manufacturers with limited capacity for basics like the inhalation drug albuterol and some common cancer treatments.
What they’re saying: Quality control issues, selected plant closures and other manufacturing woes have added up, Michael Ganio, senior director of pharmacy, practice and quality at ASHP told Axios.
Between the lines: Oncology drugs have been hit particularly hard in recent months, putting experts on high alert.
Those in short supply include methotrexate, an injectable chemotherapy drug, and one of several generics produced by Illinois-based Akorn Pharmaceuticals, which shuttered operations last month due to bankruptcy.
Manufacturing delays and increased demand have also led to shortages of the cancer treatments cisplatin, and fluorouracil, per ASHP.
Pluvicto — used to extend survival among patients with metastatic prostate cancer — will take months to be made available to patients again, the Wall Street Journal reports.
“People will die from this shortage, for sure,” Jonathan McConathy, director of the division of molecular imaging and therapeutics at the University of Alabama, told WSJ.
A survey of health systems conducted by the group End Drug Shortages Alliance found the injectable Bacillus Calmette-Guerin (BCG), used for treating bladder cancer, was being rationed or was not available for use at all.
“This is a terrible crisis. We should be doing everything we can to give every single one of these patients the best chance of survival,” Laura Bray, a board member of the alliance, told CNN.
Between the lines: Manufacturing delays and quality problems are blamed for the shortages. But that’s often because there aren’t many alternative sites to pick up the slack in the system due to the challenging economics of the market, experts say.